Leucid Bio Commences AERIAL Trial with First Patient Dosed for Innovative NKG2D CAR-T Therapy Leucid Bio has initiated its AERIAL trial by treating the first patient with LEU011, a pioneering CAR-T therapy for solid tumors, marking a significant milestone.

Leucid Bio Commences AERIAL Trial with First Patient Dosed for Innovative NKG2D CAR-T Therapy #London #United_Kingdom #CAR-T_therapy #Leucid_Bio #LEU011